ESMO-IO 2019 - ESMO Immuno-Oncology Congress 2019
Dec 11 - Dec 14, 2019 | GenevaSwitzerland
LARVOL is not affiliated with ESMO Immuno-Oncology Congress 2019 and all trademarks, logos, and brand names are property of their respective owners
Showing 34 abstracts linked to Trials
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 Part 2 final analysis
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data
Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours
A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC)
Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer
First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers
Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer
Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine
Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy
Immunotherapy in patients with relapsed/refractory HIV-related lymphomas
FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)